RBP-7000

DRUG6 trials

Sponsors

Indivior Inc.

Conditions

Schizophrenia

Phase 1

PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia

CompletedNCT02687984

Indivior Inc.Schizophrenia

Start: 2016-02-29End: 2016-05-31Updated: 2017-01-31

First in Man Study of Safety, Tolerability and PK Profile of RBP-7000

CompletedNCT02765555

Indivior Inc.Schizophrenia

Start: 2010-03-31End: 2010-09-30Updated: 2016-05-06

Single Ascending Dose Study of RBP-7000

CompletedNCT02768649

Indivior Inc.Schizophrenia

Start: 2011-04-30End: 2012-02-29Updated: 2016-05-11

Phase 2

Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy

CompletedNCT01677377

Indivior Inc.Schizophrenia

Start: 2012-08-31End: 2013-04-30Updated: 2018-10-23

Phase 3

Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients

CompletedNCT02109562

Indivior Inc.Schizophrenia

Start: 2014-04-30End: 2014-11-30Updated: 2018-10-26

Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia

CompletedNCT02203838

Indivior Inc.Schizophrenia

Start: 2014-06-30End: 2016-09-30Updated: 2018-09-28

Related Papers

PANSS Individual Item and Marder Dimension Analyses From a Pivotal Trial of RBP-7000 (Monthly Extended-Release Risperidone) in Schizophrenia Patients

The Journal of Clinical Psychiatry2021-09-2111 citations

Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia

Journal of Clinical Psychopharmacology2019-07-2422 citations

F27. EFFICACY OF MONTHLY EXTENDED-RELEASE RISPERIDONE INJECTIONS (RBP-7000) FOR THE TREATMENT OF SCHIZOPHRENIA: AN ANALYSIS OF INDIVIDUAL PANSS ITEMS

Schizophrenia Bulletin2019-04-01